Table 1.
Characteristics of PPMI subjects with PD diagnosis at recruitment.
| PD subjects (n = 360) |
Male subjects (n = 238) |
Female subjects (n = 122) |
p | |
|---|---|---|---|---|
| Baseline demographic characteristics | ||||
| Age, years |
61.23 (9.75) (33.5, 84.9) |
61.77 (9.99) (34.8, 84.9) |
60.15 (9.22) (33.5, 81.8) |
0.14 |
| No. of subjects aged > 65 |
141 (39.2%) |
102 (42.9%) |
39 (32%) |
n/a |
| BMI |
27.01 (4.62) (16.7, 43.8) |
27.82 (4.55) (19.8, 41.6) |
25.45 (4.62) (16.7. 43.8) |
< 0.001 |
| Duration since clinical diagnosis, months |
6.39 (6.36) (0, 36) |
6.13 (5.77) (0, 35) |
6.91 (7.44) (1, 36) |
0.29 |
| Education, years |
15.57 (2.94) (5, 26) |
15.72 (3.01) (5, 26) |
15.27 (2.85) (5, 22) |
0.17 |
| Dopaminergic replacement therapy | ||||
| No of subjects on DRT at year 5 |
329 (91.4%) |
223 (93.7%) |
106 (86.9%) |
n/a |
| LEDD |
581.6 (712.4) (507, 655) |
581.2 (721.6) (4687, 675) |
582.2 (700.7) (461, 704) |
0.99 |
| Gastrointestinal symptoms | ||||
| Constipation score |
1.00 (1.25) (0, 6) |
0.96 (1.22) (0, 6) |
1.08 (1.30) (0, 6) |
0.37 |
| No. of subjects with constipation score > 3 |
17 (4.7%) |
10 (4.2%) |
7 (5.7%) |
n/a |
| Sleep behavior disorders | ||||
| RDBSQ |
3.99 (2.64) (0, 12) |
4.16 (2.79) (0, 12) |
3.66 (2.30) (0, 12) |
0.09 |
| No. of subjects with RBDSQ > 5 |
87 (24.2%) |
48 (20.2%) |
39 (32%) |
n/a |
| Neuropsychological tests | ||||
| MoCA |
27.16 (2.22) (19, 30) |
26.94 (2.05) (19, 30) |
27.60 (2.28) (21, 30) |
0.008 |
| No. of subjects with MoCA < 26 |
80 (22.2%) |
55 (23.1%) |
25 (20.5%) |
n/a |
| SDMT |
41.68 (9.81) (7, 82) |
40.32 (9.77) (7, 76) |
44.36 (9.35) (7, 82) |
< 0.001 |
| LNS |
10.68 (2.60) (4, 20) |
10.54 (2.70) (4, 20) |
10.95 (2.38) (5, 20) |
0.16 |
| Semantic fluency |
49.42 (11.73) (20, 103) |
49.67 (12.28) (20, 103) |
48.94 (10.61) (25, 81) |
0.58 |
| JLO |
13.00 (1.96) (4, 15) |
13.01 (1.90) (7, 15) |
12.98 (2.08) (4, 15) |
0.87 |
| HVLT-R discrimination recognition |
10.30 (1.70) (0, 17) |
10.07 (1.40) (0, 17) |
10.76 (2.17) (7, 15) |
< 0.001 |
| HVLT-R immediate recall |
24.62 (4.95) (9, 36) |
23.73 (4.90) (9, 35) |
26.36 (4.60) (13, 36) |
< 0.001 |
| HVLT-R delayed recall |
8.47 (2.49) (0, 12) |
8.03 (2.56) (0, 12) |
9.35 (2.09) (4, 12) |
< 0.001 |
| HVLT-R retention |
1.08 (0.23) (0, 2.43) |
1.09 (0.25) (0, 2.43) |
1.06 (0.19) (0.64, 1.75) |
0.23 |
Data are shown as mean (SD) (range) or frequency (%).
Data with disease duration were missing for 8 male subjects and 8 female subjects.
All the data between male and female PD subjects were analysed using one-way ANOVA.
BMI, Body Mass Index; HVLT-R, Hopkins Verbal Learning Test-Revised; JLO, Benton Judgement of Line Orientation; LEDD, Levodopa equivalent daily dose; LNS, Letter Number Sequencing; MoCA, Montreal Cognitive Assessment; RBDSQ, Rapid eye movement sleep behaviour disorder questionnaire; SDMT, Symbol Digit Modalities Test; n/a, Not applicable.